Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial

Reuters2026/08/27 20:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Adicet Bio’s IND for ADI-212 in metastatic castration-resistant prostate cancer.
Phase 1 enrollment is expected to start in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608271600BIZWIRE_USPR_____20260827_BW653039) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Adicet Bio wins FDA IND clearance for ADI-212 prostate cancer trial

You may also like

Crypto prices